BCTXL NASDAQ
BriaCell Therapeutics Corp.
1W: +7.5%
YTD: +22.4%
$1.15
-0.05 (-4.58%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$10.0M
52W Range0.79-1.23
Volume25,652
Avg Volume13,577
Beta-0.17
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOWilliam V. Williams
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2026-01-14
Websitebriacell.com
Bellevue Centre
West Vancouver, BC V7T 2X1
CA
West Vancouver, BC V7T 2X1
CA
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT⢠targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Latest News
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
Recent Insider Trades
No insider trades found